NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$8.1m

Last Updated

2021/04/17 23:44 UTC

Data Sources

Company Financials +

Executive Summary

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Synthetic Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SYN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: SYN's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-18.0%

SYN

3.3%

US Biotechs

1.3%

US Market


1 Year Return

45.3%

SYN

22.3%

US Biotechs

53.9%

US Market

Return vs Industry: SYN exceeded the US Biotechs industry which returned 22.3% over the past year.

Return vs Market: SYN underperformed the US Market which returned 53.9% over the past year.


Shareholder returns

SYNIndustryMarket
7 Day-18.0%3.3%1.3%
30 Day-32.9%1.6%5.3%
90 Day-35.3%-4.7%8.9%
1 Year45.3%45.3%24.1%22.3%56.6%53.9%
3 Year-95.6%-95.6%32.4%25.8%64.4%53.6%
5 Year-99.4%-99.4%44.5%33.0%120.4%95.7%

Long-Term Price Volatility Vs. Market

How volatile is Synthetic Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Synthetic Biologics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Synthetic Biologics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Synthetic Biologics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Synthetic Biologics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-14.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SYN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SYN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if SYN's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if SYN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SYN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Synthetic Biologics performed over the past 5 years?

19.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SYN is currently unprofitable.

Growing Profit Margin: SYN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SYN is unprofitable, but has reduced losses over the past 5 years at a rate of 19.1% per year.

Accelerating Growth: Unable to compare SYN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SYN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).


Return on Equity

High ROE: SYN has a negative Return on Equity (-192.39%), as it is currently unprofitable.


Financial Health

How is Synthetic Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: SYN's short term assets ($7.9M) exceed its short term liabilities ($3.0M).

Long Term Liabilities: SYN's short term assets ($7.9M) exceed its long term liabilities ($186.0K).


Debt to Equity History and Analysis

Debt Level: SYN is debt free.

Reducing Debt: SYN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SYN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SYN has less than a year of cash runway if free cash flow continues to grow at historical rates of 14.7% each year.


Dividend

What is Synthetic Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SYN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SYN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SYN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SYN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SYN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average board tenure


CEO

Steve Shallcross (59 yo)

3.33yrs

Tenure

US$1,062,249

Compensation

Mr. Steven A. Shallcross, also known as Steve, CPA, is Director at Twin Vee Powercats Co. since April 8, 2021. He has been Independent Director of Elys Game Technology, Corp. (formerly known as Newgioco Gr...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD1.06M) is above average for companies of similar size in the US market ($USD543.98K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: SYN's board of directors are considered experienced (6.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SYN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 671.5%.


Top Shareholders

Company Information

Synthetic Biologics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Synthetic Biologics, Inc.
  • Ticker: SYN
  • Exchange: AMEX
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$8.066m
  • Shares outstanding: 129.65m
  • Website: https://www.syntheticbiologics.com

Number of Employees


Location

  • Synthetic Biologics, Inc.
  • 9605 Medical Center Drive
  • Suite 270
  • Rockville
  • Maryland
  • 20850
  • United States

Listings


Biography

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/17 23:44
End of Day Share Price2021/04/16 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.